How to buy Vir Biotechnology shares
Own Vir Biotechnology shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Vir Biotechnology, Inc is a biotechnology business with stocks listed in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$44.94 – an increase of 7.23% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Vir Biotechnology
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Vir Biotechnology. Find the share by name or ticker symbol: VIR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vir Biotechnology reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$44.94, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vir Biotechnology, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Vir Biotechnology. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Vir Biotechnology share priceUse our graph to track the performance of VIR stocks over time.
Vir Biotechnology shares at a glance
|52-week range||US$25.31 - US$83.5|
|50-day moving average||US$44.7974|
|200-day moving average||US$46.1472|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-5.76|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Vir Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vir Biotechnology price performance over time
|1 week (2021-06-04)||44.94|
|1 month (2021-05-12)||14.91%|
|3 months (2021-03-12)||-14.92%|
|6 months (2020-12-11)||39.87%|
|1 year (2020-06-12)||31.33%|
Vir Biotechnology financials
|Revenue TTM||US$72.6 million|
|Gross profit TTM||US$-196,511,000|
|Return on assets TTM||-25.36%|
|Return on equity TTM||-75.7%|
|Market capitalisation||US$6 billion|
TTM: trailing 12 months
Shorting Vir Biotechnology shares
There are currently 8.6 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 0.9% up from 8.5 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR)
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 649203.69253956). Vir Biotechnology's SIR currently stands at 13.27. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 13270 shares are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 70 shares are currently held short) or 0.1237% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 124 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vir Biotechnology.
Find out more about how you can short Vir Biotechnology stock.
Vir Biotechnology share dividends
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Vir Biotechnology overview
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Frequently asked questions
More guides on Finder
How to buy Vir Biotechnology shares
Steps to owning and managing Regency Centers shares.
How to buy The Honest Company (HNST) shares from Australia
Here's everything we know so far about The Honest Company IPO and how to buy in from Australia.
How to buy Vir Biotechnology shares
Steps to owning and managing Applyflow shares.
Cheap gas providers in SA
Compare gas plans from South Australia providers. Find a better deal and switch today.
Best headphones in Australia
Our expert team of reviewers pick the best headphones in Australia, with a little help from real consumer reviews.
Best fountain pens in Australia
From the best fountain pen for beginners to the top high-end model, these are the seven best fountain pens you can buy in Australia right now.
How to buy Marqeta stock from Australia when it goes public
Here's everything we know so far about the Marqeta IPO and how to buy in from Australia.
Best shower heads in Australia
We read hundreds of customer reviews to find the best shower heads you can buy online and in-store in Australia.
How to invest in the Didi Chuxing IPO from Australia
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
How to buy Robinhood stock from Australia
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Ask an Expert